What’s in Intellia Therapeutics Inc (NTLA) After Today’s Huge Increase?

September 17, 2017 - By reb123z

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! The stock increased 3.75% or $0.82 on September 15, reaching $22.68. About 607,896 shares traded or 107.76% up from the average. Intellia Therapeutics Inc (NASDAQ:NTLA) has declined 46.16% since September 17, 2016 and is downtrending. It has underperformed by 62.86% the S&P500.
The move comes after 6 months positive chart setup for the $819.04 million company. It was reported on Sep, 17 by Barchart.com. We have $23.81 PT which if reached, will make NASDAQ:NTLA worth $40.95 million more.

Wall Street await Intellia Therapeutics Inc (NASDAQ:NTLA) to release earnings on November, 7. Analysts forecast earnings per share of $-0.49, down exactly $0.27 or 122.73 % from 2014’s $-0.22 EPS. After posting $-0.45 EPS for the previous quarter, Intellia Therapeutics Inc’s analysts now forecast 8.89 % negative EPS growth.

Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) earned “Outperform” rating by Wedbush on Tuesday, May 31. The rating was initiated by Credit Suisse with “Outperform” on Tuesday, May 31. The firm earned “Buy” rating on Friday, August 5 by Jefferies. As per Tuesday, May 31, the company rating was initiated by Jefferies. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) has “Outperform” rating given on Friday, August 5 by Leerink Swann.

More notable recent Intellia Therapeutics Inc (NASDAQ:NTLA) news were published by: Globenewswire.com which released: “Intellia Therapeutics to Present at Upcoming September Investor Healthcare …” on September 07, 2017, also Globenewswire.com with their article: “Intellia Therapeutics and CRISPR Therapeutics Announce US Patent Covering …” published on April 26, 2017, Globenewswire.com published: “Intellia Therapeutics and San Raffaele University and Research Hospital to …” on June 06, 2017. More interesting news about Intellia Therapeutics Inc (NASDAQ:NTLA) were released by: Globenewswire.com and their article: “Intellia Therapeutics Announces First Quarter 2017 Financial Results” published on May 02, 2017 as well as Globenewswire.com‘s news article titled: “Intellia Therapeutics Announces European Patent Office’s Decision to Grant …” with publication date: April 11, 2017.

Intellia Therapeutics, Inc. is a genome editing company. The company has market cap of $819.04 million. The Firm is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. It currently has negative earnings. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.